Загрузка...
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
OBJECTIVE: Low-grade serous (LGS) ovarian and primary peritoneal cancer is a rare disease with limited therapeutic options. Low response rates are observed with cytotoxic chemotherapy. However, significant responses have been reported in patients treated with bevacizumab. The objective of this study...
Сохранить в:
| Опубликовано в: : | Int J Gynecol Cancer |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4401424/ https://ncbi.nlm.nih.gov/pubmed/24978709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000190 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|